Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 1

Import of global high-risk clones is the primary driver of carbapenemase-producing in Norway Open Access

Abstract

Infections by carbapenemase-producing (CP-Pa) are concerning due to limited treatment options. The emergence of multidrug-resistant (MDR) high-risk clones is an essential driver in the global rise of CP-Pa.

Insights into the molecular epidemiology of CP-Pa are crucial to understanding its clinical and public health impact. Despite the low incidence of infections in Norway, global spread requires an understanding of regional dissemination patterns.

This study aimed to investigate the phenotypic and genotypic characteristics of CP-Pa isolates in Norway and molecular epidemiology by utilizing available metadata.

The study collection comprised all verified CP-Pa isolated in Norway from 2006 to 2022 (=67) obtained from clinical (75%; =50) or screening samples (22%; =15) or had no available information (3%; =2). Phenotypic analyses included antimicrobial susceptibility testing against clinically relevant antipseudomonal antibiotics and comparative testing for carbapenemase production using three different methods (-CARBA, IMI/IMD gradient test and Coris O.K.N.V.I RESIST-5). Whole-genome sequencing was performed to identify virulence factors, resistance determinants and genomic relatedness.

The isolates were categorized as MDR (=39) encoding Verona integron-encoded metallo--lactamase (VIM) (=28), New Delhi metallo--lactamase (NDM) (=6), imipenemase metallo--lactamase (IMP) (=4) or Guiana extended spectrum metallo--lactamase (=1) carbapenemases or extensively drug-resistant (XDR; 28) encoding VIM (=11), NDM (=9) or IMP (=8) carbapenemases. CP-Pa numbers ranged from 1 to 7 annually, peaking at 17 in 2022. Most isolates (=64) were associated with international travel or hospitalization abroad. Phylogenetic analyses identified nine clusters of closely related genomes, with one suspected case of domestic patient-to-patient transmission. Among 21 detected sequence types, several were global high-risk clones, including ST235 (=12), ST111 (=9), ST773 (=9), ST253 (=3), ST357 (=3), ST395 (=3), ST823 (=3), ST233 (=2), ST654 (=2), ST260 (=1) and ST308 (=1), covering 72% of the Norwegian isolates. ST1047 (IMP-1) and ST773 (NDM-1) were associated with Ukrainian war victims. Carbapenemase detection rates for phenotypic tests were 88% (-CARBA), 91% (IMI/IMD) and 94% (Coris) in our collection.

The study highlights the low incidence yet high genomic diversity of CP-Pa in Norway and the dominance of high-risk clones linked to imports, contributing to the high proportion of XDR.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): carbapenemase-producing , global high-risk clones , molecular epidemiology and Pseudomonas aeruginosa
Funding
This study was supported by the:
  • Universitetssykehuset Nord-Norge
    • Principle Award Recipient: ApplicableNot
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001944
2025-01-06
2025-01-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/1/jmm001944.html?itemId=/content/journal/jmm/10.1099/jmm.0.001944&mimeType=html&fmt=ahah

References

  1. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209–1223 [View Article]
     [Google Scholar]
  2. Pelegrin AC, Palmieri M, Mirande C, Oliver A, Moons P et al. Pseudomonas aeruginosa : a clinical and genomics update. FEMS Microbiol Rev 2021; 45: [View Article]
     [Google Scholar]
  3. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32:1–52 [View Article]
     [Google Scholar]
  4. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 2015; 13:42–51 [View Article] [PubMed]
     [Google Scholar]
  5. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 2019; 37:177–192 [View Article] [PubMed]
     [Google Scholar]
  6. Breidenstein EBM, de la Fuente-Núñez C, Hancock REW. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011; 19:419–426 [View Article] [PubMed]
     [Google Scholar]
  7. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev 2018; 31:e00088–17 [View Article]
     [Google Scholar]
  8. Yoon EJ, Jeong SH. Mobile carbapenemase genes in Pseudomonas aeruginosa. Front Microbiol 2021; 12:614058 [View Article] [PubMed]
     [Google Scholar]
  9. Hammoudi Halat D, Ayoub Moubareck C. The current burden of carbapenemases: review of significant properties and dissemination among gram-negative bacteria. Antibiotics 2020; 9:186 [View Article]
     [Google Scholar]
  10. Halat DH, Moubareck CA. The intriguing carbapenemases of Pseudomonas aeruginosa: current status, genetic profile, and global epidemiology. YALE J Biol Med 2022; 95:36568831
     [Google Scholar]
  11. Forero-Hurtado D, Corredor-Rozo ZL, Ruiz-Castellanos JS, Márquez-Ortiz RA, Abril D et al. Worldwide dissemination of blaKPC gene by novel mobilization platforms in Pseudomonas aeruginosa: a systematic review. Antibiotics 2023; 12:658 Epub ahead of print 1 April [View Article]
     [Google Scholar]
  12. Del Barrio-Tofiño E, López-Causapé C, Oliver A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. Int J Antimicrob Agents 2020; 56:106196 [View Article] [PubMed]
     [Google Scholar]
  13. Oliver A, Rojo-Molinero E, Arca-Suarez J, Beşli Y, Bogaerts P et al. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clin Microbiol Infect 2024; 30:469–480 [View Article] [PubMed]
     [Google Scholar]
  14. Dos Santos PAS, Rodrigues YC, Marcon DJ, Lobato ARF, Cazuza TB et al. Endemic high-risk clone ST277 is related to the spread of SPM-1-producing Pseudomonas aeruginosa during the COVID-19 pandemic period in northern Brazil. Microorganisms 2023; 11:2069 [View Article] [PubMed]
     [Google Scholar]
  15. Oliver A, Mulet X, López-Causapé C, Juan C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 2015; 21–22:41–59 [View Article] [PubMed]
     [Google Scholar]
  16. Treepong P, Kos VN, Guyeux C, Blanc DS, Bertrand X et al. Global emergence of the widespread Pseudomonas aeruginosa ST235 clone. Clin Microbiol Infect 2018; 24:258–266 [View Article] [PubMed]
     [Google Scholar]
  17. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 2018; 67:1803–1814 [View Article] [PubMed]
     [Google Scholar]
  18. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318–327 [View Article]
     [Google Scholar]
  19. Hansen F, Johansen HK, Østergaard C, Arpi M, Hansen DS et al. Characterization of carbapenem nonsusceptible Pseudomonas aeruginosa in Denmark: a nationwide, prospective study. Microb Drug Resist 2014; 20:22–29 [View Article] [PubMed]
     [Google Scholar]
  20. Ljungquist O, Haldorsen B, Pöntinen AK, Janice J, Josefsen EH et al. Nationwide, population-based observational study of the molecular epidemiology and temporal trend of carbapenemase-producing Enterobacterales in Norway, 2015 to 2021. Euro Surveill 2023; 28:ii [View Article] [PubMed]
     [Google Scholar]
  21. Stolberg RS, Hansen F, Porsbo LJ, Karstensen KT, Roer L et al. Genotypic characterisation of carbapenemase-producing organisms obtained in Denmark from patients associated with the war in Ukraine. J Glob Antimicrob Resist 2023; 34:15–17 [View Article] [PubMed]
     [Google Scholar]
  22. DANMAP 2022 Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food, and humans in denmark; 20221600–2032
  23. SWEDRES, SVARM 2023 Sales of antibiotics and occurrence of antibiotic resistance in Sweden. Solna/Uppsala.ISNN2001-7901: 2023
  24. European Centre for Disease Prevention and Control Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2022. Stockholm: ECDC; 2023 https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2022
  25. Samuelsen Ø, Buarø L, Toleman MA, Giske CG, Hermansen NO et al. The first metallo-β-lactamase identified in norway is associated with a tnic-like transposon in a pseudomonas aeruginosa isolate of sequence type 233 imported from ghana. Antimicrob Agents Chemother 2009; 53:331–332 [View Article]
     [Google Scholar]
  26. The european committee on antimicrobial susceptibility testing. routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. Version 2024; 14:0
     [Google Scholar]
  27. Swayne R, Ellington MJ, Curran MD, Woodford N, Aliyu SH. Utility of a novel multiplex TaqMan PCR assay for metallo-β-lactamase genes plus other TaqMan assays in detecting genes encoding serine carbapenemases and clinically significant extended-spectrum β-lactamases. Int J Antimicrob Agents 2013; 42:352–356 [View Article] [PubMed]
     [Google Scholar]
  28. Lim K-T, Yasin R, Yeo C-C, Puthucheary S, Thong K-L. Characterization of multidrug resistant ESBL-producing Escherichia coli isolates from hospitals in Malaysia. J Biomed Biotechnol 2009; 2009:165637 [View Article] [PubMed]
     [Google Scholar]
  29. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M et al. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012; 19:455–477 [View Article] [PubMed]
     [Google Scholar]
  30. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res 2018; 3:124 [View Article] [PubMed]
     [Google Scholar]
  31. Thrane SW, Taylor VL, Lund O, Lam JS, Jelsbak L. Application of whole-genome sequencing data for o-specific antigen analysis and in silico serotyping of Pseudomonas aeruginosa isolates. J Clin Microbiol 2016; 54:1782–1788 [View Article]
     [Google Scholar]
  32. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM et al. Phandango: an interactive viewer for bacterial population genomics. Bioinformatics 2017; 1–2btx610 [View Article]
     [Google Scholar]
  33. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281 [View Article] [PubMed]
     [Google Scholar]
  34. Castanheira M, Doyle TB, Hubler CM, DeVries S, Shortridge D. Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation. mSphere 2023; 8: [View Article]
     [Google Scholar]
  35. Bernabeu S, Dortet L, Naas T. Evaluation of the β-CARBATM test, a colorimetric test for the rapid detection of carbapenemase activity in gram-negative bacilli. J Antimicrob Chemother 2017; 72:1646–1658 [View Article] [PubMed]
     [Google Scholar]
  36. Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother 2013; 57:1361–1368 [View Article]
     [Google Scholar]
  37. Moskowitz SM, Ernst RK, Miller SI. PmrAB, A two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004; 186:575–579 [View Article] [PubMed]
     [Google Scholar]
  38. Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 2017; 49:526–535 [View Article] [PubMed]
     [Google Scholar]
  39. Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics 2022; 11:723 [View Article]
     [Google Scholar]
  40. Luscher A, Moynié L, Auguste PS, Bumann D, Mazza L et al. TonB-dependent receptor repertoire of Pseudomonas aeruginosa for uptake of siderophore-drug conjugates. Antimicrob Agents Chemother 2018; 62: [View Article]
     [Google Scholar]
  41. Kriz R, Spettel K, Pichler A, Schefberger K, Sanz-Codina M et al. In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol. J Antibiot 2024; 77:757–767 [View Article] [PubMed]
     [Google Scholar]
  42. Streling AP, Al Obaidi MM, Lainhart WD, Zangeneh T, Khan A et al. Evolution of cefiderocol non-susceptibility in Pseudomonas aeruginosa in a patient without previous exposure to the antibiotic. Clin Infect Dis 2021; 73:e4472–e4474 [View Article] [PubMed]
     [Google Scholar]
  43. Simonsen GS, Salvesen Blix H, Olli Helgesen K. Usage of antimicrobial agents and occurrence of antimicrobial resistance in norway. Tromsø / Ås issn 20231890–9965
     [Google Scholar]
  44. Wang C, Yang D, Wang Y, Ni W. Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence. Front Pharmacol 2022; 13: [View Article]
     [Google Scholar]
  45. Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH et al. New β-lactam–β-lactamase inhibitor combinations. Clin Microbiol Rev 2021; 34:1–61 [View Article]
     [Google Scholar]
  46. Bahr G, González LJ, Vila AJ. Metallo-β-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design. Chem Rev 2021; 121:7957–8094 [View Article] [PubMed]
     [Google Scholar]
  47. Sader HS, Mendes RE, Kimbrough JH, Hubler CM, Castanheira M. Activity of aztreonam/avibactam and recently approved β-lactamase inhibitor combinations against Enterobacterales and Pseudomonas aeruginosa from intensive care unit and non-intensive care unit patients. Antibiotics 2024; 13:564 [View Article] [PubMed]
     [Google Scholar]
  48. Zwittink RD, Wielders CC, Notermans DW, Verkaik NJ, Schoffelen AF et al. Multidrug-resistant organisms in patients from Ukraine in the Netherlands, March to August 2022. Euro Surveill 2022; 27:2200896 [View Article] [PubMed]
     [Google Scholar]
  49. Witteveen S, Hans JB, Izdebski R, Hasman H, Samuelsen Ø et al. Dissemination of extensively drug-resistant NDM-producing Providencia stuartii in Europe linked to patients transferred from Ukraine, March 2022 to March 2023. Euro Surveill 2024; 29:2300616 [View Article] [PubMed]
     [Google Scholar]
  50. Schultze T, Hogardt M, Velázquez ES, Hack D, Besier S et al. Molecular surveillance of multidrug-resistant Gram-negative bacteria in Ukrainian patients, Germany, March to June 2022. Eurosurveillance 2023; 28: [View Article]
     [Google Scholar]
  51. Mc Gann PT, Lebreton F, Jones BT, Dao HD, Martin MJ et al. Six extensively drug- resistant bacteria in an injured soldier, Ukraine. Emerg Infect Dis 2023; 29:1692–1695 [View Article]
     [Google Scholar]
  52. Hernández-García M, Cabello M, Ponce-Alonso M, Herrador-Gómez PM, Gioia F et al. First detection in Spain of NDM-1-producing Pseudomonas aeruginosa in two patients transferred from Ukraine to a university hospital. J Glob Antimicrob Resist 2024; 36:105–111 [View Article] [PubMed]
     [Google Scholar]
  53. Chew KL, Octavia S, Ng OT, Marimuthu K, Venkatachalam I et al. Challenge of drug resistance in Pseudomonas aeruginosa: clonal spread of NDM-1-positive ST-308 within a tertiary hospital. J Antimicrob Chemother 2019; 74:2220–2224 [View Article] [PubMed]
     [Google Scholar]
  54. Salem S, Abdelsalam NA, Shata AH, Mouftah SF, Cobo-Díaz JF et al. Unveiling the microevolution of antimicrobial resistance in selected Pseudomonas aeruginosa isolates from Egyptian healthcare settings: a genomic approach. Sci Rep 2024; 14:15500 [View Article] [PubMed]
     [Google Scholar]
  55. Singh S, Pulusu CP, Pathak A, Pradeep BE, Prasad KN. Complete genome sequence of an extensively drug-resistant Pseudomonas aeruginosa ST773 clinical isolate from North India. J Glob Antimicrob Resist 2021; 27:244–246 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001944
Loading
Import of global high-risk clones is the primary driver of carbapenemase-producing Pseudomonas aeruginosa in Norway
J. Med. Microbiol. 74, 001944 (2025); https://doi.org/10.1099/jmm.0.001944
/content/journal/jmm/10.1099/jmm.0.001944
/content/journal/jmm/10.1099/jmm.0.001944
Loading

Data & Media loading...

Supplements

Supplementary material 1

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error